

1 **Modeling effectiveness of testing strategies to prevent COVID-19 in nursing homes —United**
2 **States, 2020**

3 **Authors:** Isaac See, MD¹, Prbasaj Paul, PhD¹, Rachel B. Slayton, PhD¹, Molly K. Steele, PhD¹,
4 Matthew J. Stuckey, PhD¹, Lindsey Duca, PhD^{1,2}, Arjun Srinivasan, MD¹, Nimalie Stone, MD¹,
5 John A. Jernigan, MD¹, Sujan C. Reddy, MD¹

6

7 **Affiliations:**

8 ¹CDC COVID-19 Response Team, Atlanta, GA, United States

9 ²Epidemic Intelligence Service, CDC, Atlanta, GA, United States

10

11 **Keywords:** nursing homes, testing, COVID-19, infection control, public health

12

13 **Running title:** COVID-19 nursing home testing strategies (limit: 40 characters)

14

15 **Post-publication corresponding author and alternate pre-publication corresponding author:**
16 Sujan Reddy, 1600 Clifton Rd HT 16-3, Centers for Disease Control and Prevention, Atlanta, GA
17 30329, (404) 718-6665, sreddy2@cdc.gov

18 **Pre-publication corresponding author:** Isaac See, 1600 Clifton Rd HT 16-3, Centers for Disease
19 Control and Prevention, Atlanta, GA 30329, (404) 639-0028, isee@cdc.gov

20

21 **Article type:** major article

22

23 **Word count:** 2999 (limit 3000)

24

25 **Summary** (limit: 40 words) Mathematical modeling evaluated the effectiveness of serially
26 testing asymptomatic persons in a nursing home in response to a SARS-CoV-2 outbreak with or
27 without serial testing of asymptomatic staff in the absence of known SARS-CoV-2 infections.

28

29

30

31 **Abstract:**

32

33 **Background:** SARS-CoV-2 outbreaks in nursing homes can be large with high case fatality.
34 Identifying asymptomatic individuals early through serial testing is recommended to control
35 COVID-19 in nursing homes, both in response to an outbreak (“outbreak testing” of residents
36 and healthcare personnel) and in facilities without outbreaks (“non-outbreak testing” of
37 healthcare personnel). The effectiveness of outbreak testing and isolation with or without non-
38 outbreak testing was evaluated.

39 **Methods:** Using published SARS-CoV-2 transmission parameters, the fraction of SARS-CoV-2
40 transmissions prevented through serial testing (weekly, every three days, or daily) and isolation
41 of asymptomatic persons compared to symptom-based testing and isolation was evaluated
42 through mathematical modeling using a Reed-Frost model to estimate the percentage of cases
43 prevented (i.e., “effectiveness”) through either outbreak testing alone or outbreak plus non-
44 outbreak testing. The potential effect of simultaneous decreases (by 10%) in the effectiveness
45 of isolating infected individuals when instituting testing strategies was also evaluated.

46 **Results:** Modeling suggests that outbreak testing could prevent 54% (weekly testing with 48-
47 hour test turnaround) to 92% (daily testing with immediate results and 50% relative sensitivity)
48 of SARS-CoV-2 infections. Adding non-outbreak testing could prevent up to an additional 8% of
49 SARS-CoV-2 infections (depending on test frequency and turnaround time). However, added
50 benefits of non-outbreak testing were mostly negated if accompanied by decreases in infection
51 control practice.

52 **Conclusions:** When combined with high-quality infection control practices, outbreak testing
53 could be an effective approach to preventing COVID-19 in nursing homes, particularly if
54 optimized through increased test frequency and use of tests with rapid turnaround.

55

56 **Word count:** 248 (limit 250)

57

58

59 Introduction

60 Coronavirus disease 2019 (COVID-19) has posed a significant public health challenge for nursing
61 homes in the United States [1,2]. To prevent introduction and transmission of SARS-CoV-2,
62 nursing homes have been recommended to implement precautions including monitoring
63 symptoms of residents and healthcare personnel (HCP), testing symptomatic persons promptly,
64 and instituting infection control practices including, but not limited to, isolating individuals with
65 COVID-19 [3]. In addition, because asymptomatic and pre-symptomatic infected individuals can
66 transmit SARS-CoV-2, identifying such infected individuals early through serial testing is also
67 recommended to control COVID-19 in nursing homes both as part of an outbreak response as
68 well as in facilities not experiencing outbreaks [4–6]. When responding to an outbreak, CDC
69 currently recommends testing all residents and HCP every 3–7 days until no new cases are
70 identified. In addition, in facilities not experiencing an outbreak, serial testing of all HCP is
71 currently recommended, at intervals dependent on the level of county transmission [6].

72 Infection prevention and control strategies in nursing homes might be hampered by
73 shortages of testing supplies [7] and the time-consuming effort needed to implement
74 widespread testing strategies. The impact of various testing strategies for asymptomatic
75 residents and HCP has not been well characterized; understanding the relative benefit of
76 testing strategies may help prioritize resources. The objective of this manuscript is to provide
77 estimates of the effectiveness (i.e., percentage of COVID-19 cases prevented) of either
78 outbreak testing or combining outbreak and non-outbreak testing for preventing COVID-19 in
79 nursing homes under different scenarios of test frequency and performance. We also estimate
80 the “efficiency” (number of tests needed to prevent a case) of both outbreak and non-outbreak
81 testing strategies.

83 Methods

84 *Definitions*

85 “Outbreak testing” was defined as serial testing (e.g., daily, every three days, weekly) of all
86 residents and HCP immediately following recognition of an initial COVID-19 case. “Non-
87 outbreak testing” was defined as serial testing of HCP in the absence of a known COVID-19
88 case. Mathematical modeling was used to evaluate two paradigms for using testing to help
89 control COVID-19 in nursing homes: (1) outbreak testing that begins immediately following
90 recognition of an initial case, and (2) non-outbreak testing in facilities when outbreaks are not
91 occurring combined with outbreak testing once cases are identified. Testing frequency,
92 turnaround time, and sensitivity were varied to broadly reflect testing capabilities as of
93 November 2020. The primary quantities of interest were the “effectiveness” of a testing
94 strategy, defined as the percent of cases prevented; and the “efficiency” of a testing strategy,
95 defined as the number of cases prevented divided by the number of tests used.

96 Evaluating these strategies for a “typical” nursing home required estimating three
97 quantities through modeling: (1) the expected number of SARS-CoV-2 infections occurring in an
98 outbreak without testing of asymptomatic persons, i.e., infection control is guided only by
99 testing and isolating symptomatic residents and HCP. This quantity is considered the “baseline”
100 outbreak size because, conceptually, our evaluation is for paradigms of testing asymptomatic
101 persons. (2) the expected number of SARS-CoV-2 infections occurring per outbreak when
102 outbreak testing is conducted. The difference between (2) and (1) is the number of cases
103 prevented by outbreak testing. (3) the expected percentage of SARS-CoV-2 outbreaks prevented
104 by non-outbreak testing.

105 Parameters used for the model and estimates were set as follows: during the early
106 months of the pandemic the mean number of residents from Centers for Medicare & Medicaid
107 Services (CMS)-certified nursing homes was 86 [8]. The HCP per resident ratio was set at 1.5:1,
108 yielding 129 HCP at the facility based on the following rationale: analysis of the payroll-based
109 journal data from the Centers for Medicare and Medicaid Services (PBJ) suggest that on
110 average 1.2 full-time equivalent HCP per resident are employed by each nursing home [9].
111 However, this likely represents a minimum estimate because some HCP work part-time. In
112 some areas where facility-wide testing of and residents has been conducted, the HCP per
113 resident ratio has been as high as 2:1 (CDC, unpublished data). The ratio of 1.5 HCP per
114 resident was chosen as closer to the midpoint of these estimates. Although these HCP
115 estimates HCP may include some who do not have direct resident contact, such HCP could still
116 contribute to SARS-CoV-2 transmission (e.g., HCP-to-HCP). Estimates of infectivity from
117 asymptomatic or pre-symptomatic persons [10] varied over the course of illness and were used
118 to calculate the expected reduction of transmission occurring from detecting these people
119 through testing and isolating them (supplemental methods). All scenarios model introductions
120 of SARS-CoV-2 into the facility through HCP only, e.g., no visitors are permitted. A summary of
121 model inputs can be found in Table 1.

122

123 *Calculation of estimates*

124 To estimate the expected size of an outbreak at baseline, a Reed-Frost model, in which
125 the susceptible individuals in a population of size N have probability $p = \frac{R}{N-1}$ of becoming
126 infected at each stage of transmission [11], was used to model the transmission of SARS-CoV-2
127 during a nursing home outbreak. The Reed-Frost model was chosen because it is well-suited for
128 capturing stochasticity of transmissions in finite-sized congregate settings. The total population
129 size is the number of residents plus the number of HCP. We estimated the reproductive
130 number R_0 for outbreaks under the following conditions: (1) the only testing occurring was of
131 symptomatic persons, (2) isolation of symptomatic persons occurred, and (3) recommendations
132 for other established infection control practices (e.g., isolating patients, universal facemasks
133 and cloth face coverings) were in place. This estimate of R_0 , based on data for nursing home

134 outbreaks from Colorado during the early period of the pandemic (supplemental methods), is
135 referred to as the “unmitigated” R_0 and used to generate the baseline outbreak size.

136 To determine outbreak size when using outbreak testing, modeling based on viral
137 dynamics of SARS-CoV-2 was used to estimate the reduction in transmission μ expected from
138 the testing strategy (supplemental methods). The mitigated reproductive number R_0' was
139 calculated by multiplying the unmitigated R_0 by the reduction in transmission μ expected from
140 the testing strategy and used to estimate outbreak size using outbreak testing.

141 For non-outbreak testing, the proportion of outbreaks prevented was set to equal μ .
142 This corresponds to an assumption that an outbreak (at baseline) will typically be introduced by
143 a single person so that the proportion of transmissions prevented equals the proportion of
144 outbreaks averted and represents a best-case scenario for non-outbreak testing regardless of
145 the level of community transmission. As outlined in the supplemental methods, this was
146 combined with estimates for outbreak testing to determine the effectiveness and efficiency of
147 using both outbreak and non-outbreak testing.

148 The “baseline” test sensitivity was modeled to vary during the course of illness with test
149 sensitivity proportional to infectiousness early in the course of illness (supplemental methods).
150 Peak sensitivity was set at 95% reflecting best understanding of reported reverse-transcriptase
151 polymerase chain reaction (RT-PCR) test characteristics [12]. To mirror realistic and
152 recommended tests available, outbreak and non-outbreak testing strategies were primarily
153 evaluated with weekly and every-three-days testing intervals with either a 24-hour or 48-hour
154 turnaround time and sensitivity corresponding to RT-PCR; or an estimated sensitivity of 85%
155 (compared to RT-PCR tests), with immediate turnaround time, i.e., point-of-care test
156 (supplemental methods). The lower sensitivity of 85% was chosen to match the lower end of
157 the range of sensitivity reported for currently available point-of-care tests [13]. We also
158 evaluated a hypothetical outbreak and non-outbreak testing strategy in which a point-of-care
159 test with 50% sensitivity is used for daily testing. These testing scenarios with lower sensitivity
160 were evaluated because some investigators have advocated for the development and adoption
161 of rapid tests with lower sensitivity [14]. We also evaluated weekly and every-three-days
162 testing with a lower sensitivity (50%) point-of-care platform because of reports that existing
163 point-of-care tests may have lower sensitivity for detecting asymptomatic individuals [15].

164

165 *Sensitivity analyses and other variations*

166 The above analyses evaluated the impact of adding non-outbreak testing to outbreak
167 testing with a 10% probability of SARS-CoV-2 introduction to a facility during the week that
168 testing occurs, which corresponded to the overall national picture during July-September 2020
169 (supplemental methods). As a sensitivity analysis, this probability was increased to evaluate the
170 potential impact of non-outbreak testing in areas with higher levels of community transmission.

171 We considered that implementing a more comprehensive testing strategy require
172 additional resources (e.g., staff time, protective equipment). We postulated that these
173 increases might have a deleterious effect on a facility's ability to control transmission through
174 adherence to infection control protocols. To estimate this effect, we calculated the impact of a
175 relatively small (i.e., 10%) decrease (from a default of 100%) in the effectiveness of preventing
176 transmission by isolating infected persons when adding non-outbreak testing to outbreak
177 testing.

178 Additional sensitivity analyses used adaptations of three alternate infectivity profiles
179 from the literature to calculate the above quantities (supplemental methods; supplemental
180 table S1).

181

182 *Administrative information*

183 Modeling calculations were conducted with the statistical software R (version 4.0.2, the
184 R Foundation for Statistical Computing). Additional details about modeling can be found in a
185 supplemental section. Code for the models can be found on the CDC Epidemic Prediction
186 Initiative GitHub site (<https://github.com/cdcepi/Nursing-home-SARS-CoV-2-testing-model/>).

187 This activity was reviewed by CDC and was conducted consistent with applicable federal
188 law and CDC policy (see e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C
189 §552a; 44 U.S.C. §351 et seq.).

190

191 **Results:**

192 *Effectiveness and efficiency of outbreak and non-outbreak testing*

193 At all currently recommended testing intervals with acceptable turnaround times (i.e., 48 hours
194 or less), outbreak testing alone is estimated to prevent 54% (weekly testing with 48-hour
195 turnaround time) to 90% of cases (point-of-care testing every three days) associated with a
196 COVID-19 outbreak (Table 2). Adding weekly or every-three-days non-outbreak testing to
197 outbreak testing prevented up to 8% of additional cases. Combining every-three-days outbreak
198 and non-outbreak testing with a point-of-care test prevented 95% of cases. In addition, at a
199 given testing frequency and turnaround time, increasing either the frequency of the testing or
200 decreasing the turnaround time for outbreak testing was estimated to prevent more infections
201 than adding non-outbreak testing with the same frequency and turnaround time. In an
202 exploratory analysis, use of a daily POC test with 50% sensitivity was estimated to prevent 92%
203 of cases using outbreak testing alone and 97% of cases using both outbreak and non-outbreak
204 testing.

205 Combining outbreak and non-outbreak testing in the setting of a 10% decrease in the
206 effectiveness of isolating infected persons prevented fewer cases than outbreak testing alone

207 with complete effectiveness of isolation for all testing frequencies, turnaround, and test
208 sensitivity scenarios evaluated except when testing every three days with 24-hour turnaround
209 time or POC testing with 85% sensitivity. In these scenarios, adding non-outbreak testing but
210 decreasing effectiveness of isolating infected persons was estimated to prevent an additional 2-
211 3% of cases compared to outbreak testing alone with complete effectiveness of isolation.

212 The number of tests needed to prevent a case through outbreak testing alone (range:
213 41-145 tests/case prevented) was lower than through combining outbreak and non-outbreak
214 testing (range: 60-238).

215

216 *Varying likelihood of SARS-CoV-2 introduction from the community*

217 When conducting outbreak and non-outbreak testing every three days with a point-of-
218 care test with 85% sensitivity, as the likelihood of SARS-CoV-2 introductions per week
219 increased, the percent of cases prevented was estimated to remain unchanged at 95% (Figure).
220 However, as the likelihood of SARS-CoV-2 introductions increased, the number of tests needed
221 to prevent a case was estimated to decrease from 90 tests/case prevented at a 10% likelihood
222 of introductions to 9 tests/case prevented at a 100% likelihood of introductions when
223 combining outbreak and non-outbreak testing (Figure).

224

225 *Sensitivity analyses*

226 As a sensitivity analysis when using alternative infectivity profiles (Table S1), the
227 magnitude of benefit of outbreak testing varied (Tables S2-S4). For example, testing weekly
228 with 48-hour turnaround prevented 31–74% of infections depending on the infectivity profile.
229 However, in all of these sensitivity analyses adding non-outbreak testing added a relatively
230 small percentage benefit to outbreak testing alone, not exceeding 8% for any test
231 turnaround/frequency/sensitivity regardless of infectivity profile. In addition, for all but one
232 infectivity profile (Table S4), for the majority of testing scenarios modeled outbreak testing
233 alone was superior to combining outbreak and non-outbreak testing if combined testing was
234 associated with decreases in effectiveness of isolating patients.

235

236 **Discussion**

237 Preventing COVID-19 in nursing homes is a high priority for the pandemic response [16]. In our
238 analysis, serially testing asymptomatic residents and HCP in response to an outbreak to guide
239 infection control response prevented the majority of SARS-CoV-2 infections in a hypothetical
240 nursing home with 86 residents and 129 staff. In addition, optimizing and prioritizing outbreak
241 testing to facilitate increased test frequency with rapid turnaround times while maintaining

242 high-quality infection control practice is estimated to be an efficient strategy while also nearly
243 maximizing number of infections prevented.

244 Ensuring robust symptom identification with prompt testing in response to a potential
245 new SARS-CoV-2 infection, and subsequently eliminating transmission from persons with
246 COVID-19 through isolation, is essential for responses using outbreak testing to be effective.
247 Nursing homes with outbreaks frequently face staff shortages [17], which may limit capacity to
248 perform necessary patient care activities, infection prevention activities, or increased testing. If
249 redirecting resources from recommended infection control practices to testing leads to small
250 reductions in the effectiveness of infection control practices, then the combination of outbreak
251 and non-outbreak testing could be less effective than just performing outbreak testing with
252 high-quality infection control. These considerations are all the more important because real-
253 life conditions in a nursing home might not correspond to ideal implementation. For example,
254 isolation of patients can be difficult if there are no empty rooms; and isolated patients still need
255 care and therefore could still pose some risk of transmission to staff.

256 These findings also support current recommendations from CDC and CMS [6,18] to
257 prioritize testing of symptomatic residents and HCP first, followed by testing residents and staff
258 in response to outbreaks, and finally non-outbreak testing of asymptomatic HCP. The addition
259 of non-outbreak testing may provide a modest benefit, although it requires more testing
260 resources to prevent each COVID-19 case. The testing resources required (per case prevented)
261 did decrease as the likelihood of SARS-CoV-2 introductions (i.e., level of community
262 transmission) increased. The impact is still only modest even when SARS-CoV-2 introductions
263 are more frequent than observed in the United States in July-September 2020. The reason that
264 non-outbreak testing only has a modest benefit is that the benefit of non-outbreak testing
265 relies on the ability to identify infected persons at key times in the course of their illness: the
266 pre-symptomatic infectious period and, for asymptomatic individuals, the period of peak
267 infectiousness. Both of these time periods are narrow (e.g., pre-symptomatic period of 2-3
268 days) and easily missed without very frequent (e.g., every-three-days or more often) testing
269 [10,14]. Furthermore, implementing high-quality outbreak response leads to smaller outbreaks,
270 which then reduces the added benefit of non-outbreak testing because the outbreaks
271 prevented through non-outbreak testing are smaller in size.

272 The results described in this paper also support current recommendations that
273 performing outbreak testing every three days is the preferred frequency when initiating an
274 outbreak response, if this does not detract from other important activities such as infection
275 control procedures [18]. In general, testing strategies with better turnaround time and higher
276 frequency were estimated to be more effective if other conditions (e.g., infection control
277 practices) remained constant.

278 The federal government is providing nursing homes with point-of-care antigen testing
279 platforms [19]. The analysis conducted in this manuscript suggests that the advantage of faster
280 turnaround time from such platforms may outweigh the disadvantage of potential lower

281 sensitivity. Practical considerations may still limit how frequently these tests can be performed
282 through serial testing strategies. An exploratory analysis suggested that a hypothetical strategy
283 using daily point-of-care testing with lower (e.g., 50%) sensitivity could be as effective as, or
284 even more effective than, relying on more sensitive tests used less frequently. Daily testing is
285 likely not currently feasible in all nursing homes and would need widespread availability of
286 inexpensive, simple testing options that could be run on easy-to-collect specimen types. In
287 addition, making a test with 50% sensitivity available (that might facilitate daily testing) would
288 require changes to the current regulatory framework [20–24].

289 These findings are subject to at least the following limitations. First, the analysis used
290 mathematical modeling rather than directly studying an implementation. However, the model
291 parameters have been reviewed as suitable to use for pandemic planning scenarios and are
292 based on observational data about SARS-CoV-2 transmission [10]. The patterns seen and
293 comparisons made from results, therefore, are likely reasonable even if the absolute estimates
294 themselves may lack precision. Second, outbreaks in facilities have been assumed to be
295 independent. Since some HCP work in more than one facility [4], the potential effectiveness of
296 both testing strategies has been underestimated on a population level. Third, other unintended
297 consequences of asymptomatic testing were not evaluated, such as identifying false positives
298 during non-outbreak testing with population prevalence of COVID-19. Even if using a test with
299 99.4% specificity, most facilities without COVID-19 might expect at least one false positive
300 result after testing all its staff. Fourth, there is uncertainty around the parameters used for the
301 model. For example, the actual infectivity profile of SARS-CoV-2 infection is not known with
302 certainty, although our main conclusions appear to be robust when evaluating several
303 published infectivity profiles. As another example, the proportion of patients with
304 asymptomatic infections has varied in the reported literature [25,26]. Fifth, we have not
305 accounted for how the accumulation of persons with immunity over the course of time might
306 affect strategies. Finally, if infection control practices, in general, are not optimal, then the
307 benefits of testing strategies will be less than we have estimated. For example, we assume that
308 outbreak testing occurs immediately after identification of a recognized case, while in practice
309 delays could occur.

310 In summary, testing asymptomatic persons in response to an outbreak is an effective
311 and efficient strategy to supplement optimized infection control practices to limit SARS-CoV-2
312 transmissions in nursing homes. The benefit of outbreak testing strategies may increase with
313 more frequent outbreak testing with rapid turnaround times, but most importantly require
314 careful effort to ensure that infection control measures are effectively implemented.

315

316 **Acknowledgements**

317 The authors would like to thank Christopher Czaja, MD, DrPH (Colorado Department of Public
318 Health and Environment) for discussions about nursing home outbreak response in Colorado
319 early in the COVID-19 pandemic.

320

321 **Conflicts of interest**

322 None

323

324 **Funding**

325 This work was funded by the Centers for Disease Control and Prevention.

326

327 **Disclaimer**

328 The findings and conclusions in this report are those of the authors and do not necessarily
329 represent the views and the official position of the Centers for Disease Control and Prevention.

330

331 **References**

- 332 1. Centers for Medicare and Medicaid Services. COVID-19 Nursing Home Data.
333 <https://data.cms.gov/stories/s/COVID-19-Nursing-Home-Data/bkwz-xpvg/>. Last
334 accessed September 25, 2020.
- 335 2. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic
336 SARS-CoV-2 infections and transmission in a skilled nursing facility. *New Engl J Med*.
337 2020 Apr 24;382(22):2081–2090.
- 338 3. Centers for Disease Control and Prevention. Preparing for COVID-19 in Nursing Homes.
339 Available at: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/long-term-care.html>.
340 Accessed 19 November 2020.
- 341 4. McMichael TM, Clark S, Pogojans S, Kay M, Lewis J, Baer A, et al. COVID-19 in a Long-
342 Term Care Facility — King County, Washington, February 27–March 9, 2020. *MMWR*
343 *Morb Mort Weekly Rep*. 2020 March 27;69(12):339-342.
- 344 5. Centers for Disease Control and Prevention. Testing Guidelines for Nursing Homes.
345 Available at: [https://www.cdc.gov/coronavirus/2019-ncov/hcp/nursing-homes-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/nursing-homes-testing.html)
346 [testing.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/nursing-homes-testing.html). Accessed 19 November 2020.
- 347 6. Centers for Medicare & Medicaid services Center for Clinical Standards and
348 Quality/Survey & Certification Group. QSO-20-38-NH. Available at:
349 <https://www.cms.gov/files/document/qso-20-38-nh.pdf>. Accessed 19 November 2020.

- 350 7. American Society for Microbiology. Supply Shortages Impacting COVID-19 and Non-
351 COVID Testing. Available at: [https://asm.org/Articles/2020/September/Clinical-](https://asm.org/Articles/2020/September/Clinical-Microbiology-Supply-Shortage-Collecti-1)
352 [Microbiology-Supply-Shortage-Collecti-1](https://asm.org/Articles/2020/September/Clinical-Microbiology-Supply-Shortage-Collecti-1) Accessed November 4, 2020
- 353 8. Centers for Medicare and Medicaid Services. Nursing Home Compare datasets.
354 Available at: <https://data.medicare.gov/data/nursing-home-compare>. Last accessed
355 October 5, 2020.
- 356 9. Centers for Medicare and Medicaid Services. PBJ Public Use Files Data Documentation.
357 Available at: [https://data.cms.gov/Special-Programs-Initiatives-Long-Term-Care-](https://data.cms.gov/Special-Programs-Initiatives-Long-Term-Care-Facili/PBJ-Public-Use-Files-Data-Documentation/ygny-gzks)
358 [Facili/PBJ-Public-Use-Files-Data-Documentation/ygny-gzks](https://data.cms.gov/Special-Programs-Initiatives-Long-Term-Care-Facili/PBJ-Public-Use-Files-Data-Documentation/ygny-gzks). Last accessed September
359 23, 2020
- 360 10. Centers for Disease Control and Prevention. COVID-19 Pandemic Planning Scenarios.
361 Available at: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html>.
362 Accessed 19 November 2020.
- 363 11. Halloran E, Longini IM Jr, Struchiner CJ. Design and Analysis of Vaccine Studies. Chapter
364 4: Binomial and Stochastic Transmission Models. Springer New York, New York, New
365 York: 2009. Available at:
366 <http://courses.washington.edu/b578a/readings/bookchap4.pdf>. Accessed 2020
367 November 20.
- 368 12. Kucirka L, Lauer S, Laeyendecker O, Boon D, Lessler J. Variation in False Negative Rate of
369 RT-PCR Based SARS-CoV-2 Tests by Time Since Exposure. medRxiv
370 2020.04.07.20051474 [Preprint]. April 10, 2020 [cited 2020 Nov 19]. Available from:
371 <https://www.medrxiv.org/content/10.1101/2020.04.07.20051474v1>
- 372 13. Centers for Disease Control and Prevention. Interim Guidance for Rapid Antigen Testing
373 for SARS-CoV-2. Available at: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html)
374 [ncov/lab/resources/antigen-tests-guidelines.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html). Accessed 2020 November 19.
- 375 14. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test sensitivity is
376 secondary to frequency and turnaround time for COVID-19 surveillance. medRxiv
377 2020.06.22.20136309 [Preprint]. September 8, 2020 [cited 2020 Nov 19]. Available
378 from: <https://www.medrxiv.org/content/10.1101/2020.06.22.20136309v3>
- 379 15. A Rapid Virus Test Falts in People Without Symptoms, Study Finds. The New York
380 Times. November 2, 2020. Available at:
381 <https://www.nytimes.com/2020/11/02/health/coronavirus-testing-guidel-sofia.html>.
382 Accessed 19 November 2020.
- 383 16. U.S. White House. President Donald J. Trump Is Taking Strong Action to Further Protect
384 Nursing Homes from the Coronavirus. Available at:
385 [https://www.whitehouse.gov/briefings-statements/president-donald-j-trump-is-taking-](https://www.whitehouse.gov/briefings-statements/president-donald-j-trump-is-taking-decisive-action-to-protect-vulnerable-citizens-in-americas-nursing-homes/)
386 [decisive-action-to-protect-vulnerable-citizens-in-americas-nursing-homes/](https://www.whitehouse.gov/briefings-statements/president-donald-j-trump-is-taking-decisive-action-to-protect-vulnerable-citizens-in-americas-nursing-homes/). Accessed
387 2020 November 19.
- 388 17. Taylor J, Carter RJ, Lehnertz N, Kazazian L, Sullivan M, Wang X, Garfin J, et al. Serial
389 Testing for SARS-CoV-2 and Virus Whole Genome Sequencing Inform Infection Risk at

- 390 Two Skilled Nursing Facilities with COVID-19 Outbreaks — Minnesota, April–June 2020.
391 MMWR Morb Mortal Wkly Rep 2020 Sep 18;69(37):1288–1295.
- 392 18. Centers for Disease Control and Prevention. Clinical Questions about COVID-19:
393 Questions and Answers. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/fag.html#Testing-in-Nursing-Homes>. Accessed 5 October 2020.
- 394
395 19. U.S. Department of Health and Human Services. Trump Administration Announces
396 Initiative for More and Faster COVID-19 Testing in Nursing Homes. Available at:
397 [https://www.hhs.gov/about/news/2020/07/14/trump-administration-announces-](https://www.hhs.gov/about/news/2020/07/14/trump-administration-announces-initiative-more-faster-covid-19-testing-nursing-homes.html)
398 [initiative-more-faster-covid-19-testing-nursing-homes.html](https://www.hhs.gov/about/news/2020/07/14/trump-administration-announces-initiative-more-faster-covid-19-testing-nursing-homes.html). Accessed 2020 November
399 20.
- 400 20. U.S. Food and Drug Administration (FDA). In Vitro Diagnostics EUAs. Available at:
401 [https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas)
402 [use-authorizations-medical-devices/vitro-diagnostics-euas](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas). Accessed 2020 November
403 27.
- 404 21. U.S. Food and Drug Administration (FDA). Molecular Diagnostic Template for
405 Commercial Manufacturers. Available at:
406 <https://www.fda.gov/media/135900/download>. Accessed 2020 November 27.
- 407 22. U.S. Food and Drug Administration (FDA). Molecular Diagnostic Template for
408 Laboratories. Available at: <https://www.fda.gov/media/135658/download>. Accessed
409 2020 November 27.
- 410 23. U.S. Food and Drug Administration (FDA). Antigen Template for Test Developers.
411 Available at: <https://www.fda.gov/media/137907/download>. Accessed 2020 November
412 27.
- 413 24. U.S. Food and Drug Administration (FDA). Template for Manufacturers of Molecular and
414 Antigen Diagnostic COVID-19 Tests for Non-Laboratory Use. Available at:
415 <https://www.fda.gov/media/140615/download>. Accessed 2020 November 27.
- 416 25. Yanes-Lane M, Winters N, Fregonese F et al. Proportion of asymptomatic infection
417 among COVID-19 positive persons and their transmission potential: A systematic review
418 and meta-analysis. PLoS One. November 3, 2020. 15(11):e0241536.
419 <https://doi.org/10.1371/journal.pone.0241536>
- 420 26. Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 transmission from people
421 without COVID-19 symptoms. JAMA Network Open. 2021;4(1):e2035057.
422
423

424

Table 1: Model inputs

Variable	Value	Source/reference
Number of residents	86	Estimated as occupied beds from Nursing home compare [8]
Number of healthcare personnel	129	1.5 times the number of residents
Total population size	215	Number of residents+healthcare personnel
R_0	1.366689	Mean R_0 estimated from outbreak sizes among Colorado nursing homes (Supplemental methods)
Proportion of transmission from symptomatic infections occurring during presymptomatic phase	0.5	CDC Pandemic Planning Scenarios [10]
Proportion of infections that are asymptomatic	0.4	CDC Pandemic Planning Scenarios [10]
Infectivity of asymptomatic versus symptomatic infections	0.75	CDC Pandemic Planning Scenarios [10]

425

Table 2:

Percent SARS-CoV-2 infections prevented and number of tests needed per case prevented when serially testing asymptomatic nursing home residents and staff in response to outbreaks (“outbreak testing”), combining this testing strategy with serial testing of asymptomatic staff in the absence of known cases (“outbreak+non-outbreak testing”), and conducting both outbreak and non-outbreak testing with a concomitant 10% decrease in the effectiveness of halting SARS-CoV-2 transmission through isolating identified cases. Cases occurring using these strategies are compared to the number occurring with use of only symptom-based testing and isolation^a.

Sensitivity ^d	Turnaround time	Testing frequency	Outbreak testing ^b		Outbreak + non-outbreak testing ^{b,c}		Outbreak + non-outbreak testing ^{b,c} , 10% decrease in effectiveness of isolation	
			% cases prevented ^e	Tests/case prevented ^e	% cases prevented ^e	Tests/case prevented ^e	% cases prevented ^e	Tests/case prevented ^e
Baseline	48 hours	Weekly	54.1%	67	61.9%	90	45.8%	130
Baseline	24 hours	Weekly	67.8%	47	75.3%	67	63.0%	86
Baseline	48 hours	Every 3 days	79.3%	80	85.9%	121	78.2%	141
Baseline	24 hours	Every 3 days	87.3%	61	92.8%	98	89.4%	106
85%	POC	Weekly	72.9%	41	80.1%	60	69.7%	74
85%	POC	Every 3 days	89.7%	55	94.8%	90	92.7%	95
50% ^f	POC	Weekly	50.9%	73	58.6%	97	41.9%	145
50% ^f	POC	Every 3 days	79.7%	79	86.2%	119	78.8%	140
50% ^f	POC	Daily	92.4%	145	97.1%	238	96.2%	246

POC: point-of-care (i.e., results available immediately)

^a In this situation a mean of 50 cases/outbreak occur.

^b Outbreak testing: serial testing of asymptomatic persons in response to an outbreak

^c Non-outbreak testing: serial testing of asymptomatic healthcare personnel in the absence of known cases

^d Sensitivities of 85% and 50% are relative to the sensitivity of the baseline test, which is modeled to vary during the course of infectiousness and to replicate sensitivity of existing reverse transcriptase polymerase chain reaction (RT-PCR) tests for SARS-CoV-2.

^e The fraction of cases prevented compared to what is expected to occur when performing neither outbreak testing nor non-outbreak testing but still maintaining effectiveness of isolating patients.

^f No point-of-care test with this sensitivity is currently available for use in the United States; this testing platform represents a hypothetical situation in that respect or may be a reflection of tests that may have low sensitivity for detecting asymptomatic persons with low viral load.

DRAFT

Figure: Evaluation of how the performance of testing strategies for nursing homes changes as the likelihood of a new SARS-CoV-2 introduction during the week of testing varies. The solid line depicts the percentage of cases prevented when combining outbreak and non-outbreak testing. The dotted line shows tests per case prevented when combining outbreak and non-outbreak testing. Both lines show results for outbreak and non-outbreak testing conducted every 3 days with immediate turnaround (i.e., point-of-care test) and 85% test sensitivity (compared to a reverse-transcriptase polymerase chain reaction [RT-PCR] test).

